N,N,3-trimethyloxetan-3-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧杂环丁烷
• 英文名称: N,N,3-trimethyloxetan-3-amine
• 化学式: C₆H₁₃NO
• 分子量: 115.17
• InChiKey: QBAXQCUYUFQFKP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• NADPH oxidase 4 inhibitors
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：US11136317B2

  公开（公告）日：2021-10-05

  The invention relates to 2,5-disubstituted benzoxazole and benzothiazole derivatives of Formula (I) wherein L, X, Y, and ring (A) are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds may be useful for the prevention or treatment of diseases or disorders associated with impaired reactive oxygen species (ROS) production, and/or for the prevention or treatment of various fibrotic diseases.

  本发明涉及式 (I) 的 2,5-二取代苯并恶唑和苯并噻唑衍生物 其中 L、X、Y 和环（A）如描述中所述，它们的制备及其作为药用活性化合物的用途。所述化合物可用于预防或治疗与活性氧（ROS）生成受损有关的疾病或紊乱，和/或预防或治疗各种纤维化疾病。
• NADPH OXIDASE 4 INHIBITORS
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：US20180179194A1

  公开（公告）日：2018-06-28

  The invention relates to 2,5-disubstituted benzoxazole and benzothiazole derivatives of Formula (I) wherein L, X, Y, and ring (A) are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds may be useful for the prevention or treatment of diseases or disorders associated with impaired reactive oxygen species (ROS) production, and/or for the prevention or treatment of various fibrotic diseases.
• [EN] SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS<br/>[FR] SULFONYLURÉES ET SULFONYLTHIOURÉES EN TANT QU'INHIBITEURS DE NLRP3
  申请人：INFLAZOME LTD

  公开号：WO2019034692A1

  公开（公告）日：2019-02-21

  The present invention relates to sulfonylureas and sulfonylthioureas comprising a 5-membered heteroaryl ring attached to the sulfonyl group, wherein the heteroaryl ring is di-substituted at the 3- and 4-positions relative to the point of attachment of the sulfonyl group, wherein at least one of the di-substituents contains a nitrogen atom. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.